PT  - JOURNAL ARTICLE
AU  - ANNA ELISABETTA BRUNETTI
AU  - SABINA DELCURATOLO
AU  - VITO LORUSSO
AU  - LOREDANA PALERMO
AU  - ANGELO DI GIORGIO
AU  - SALVATORE PISCONTI
AU  - NICOLA SILVESTRIS
TI  - Third-Line Trabectedin for a Metastatic Desmoplastic Small Round Cell Tumour Treated with Multimodal Therapy
DP  - 2014 Jul 01
TA  - Anticancer Research
PG  - 3683--3688
VI  - 34
IP  - 7
4099  - http://ar.iiarjournals.org/content/34/7/3683.short
4100  - http://ar.iiarjournals.org/content/34/7/3683.full
SO  - Anticancer Res2014 Jul 01; 34
AB  - Background: Desmoplastic small round cell tumour (DSRCT) is a rare and aggressive cancer that usually develops in the peritoneal cavity of young males. Its prognosis is dismal, with current treatment options including the combination of multi-agent chemotherapy, aggressive surgery, radiation therapy, and autologous stem cell transplantation. Hyperthermic intraperitoneal chemotherapy (HIPEC) may also be an option. Case Report: Herein we report the administration of the marine-derived multi-target antineoplastic agent, trabectedin, in a patient with DSRCT, heavily pre-treated with conventional multi-agent chemotherapy, HIPEC, and surgery. Results: The patient achieved a prolonged partial response and an extended period of stable disease with third-line trabectedin, following disease progression after conventional multi-agent chemotherapy, HIPEC, and surgery. Conclusion: Trabectedin may be a treatment option in multimodal therapy for the management of DSRCT and warrants further research to explore the impact of trabectedin in the treatment of this disease.